maccura(SZ:300463) Xin Lang Zheng Quan·2025-10-23 01:21Core Viewpoint - On October 22, 2023, Maike Bio experienced a slight increase in stock price by 0.34%, with a trading volume of 52.52 million yuan. The company reported a net financing outflow of 374,200 yuan for the day, indicating a low financing balance relative to its market value [1] Financing and Margin Trading - On October 22, Maike Bio had a financing buy-in of 6.50 million yuan and a financing repayment of 6.88 million yuan, resulting in a net financing buy-in of -374,200 yuan. The total financing and margin trading balance reached 325 million yuan [1] - The current financing balance of 323 million yuan accounts for 4.58% of the circulating market value, which is below the 30th percentile level over the past year, indicating a low position [1] - In terms of margin trading, Maike Bio repaid 1,900 shares and sold 100 shares on October 22, with a selling amount of 1,167 yuan. The remaining margin balance is 1.57 million yuan, which exceeds the 90th percentile level over the past year, indicating a high position [1] Company Overview - Maike Bio, established on October 20, 1994, and listed on May 28, 2015, is located in Chengdu, Sichuan Province. The company focuses on the research, production, sales, and related services of in vitro diagnostic products [1] - The main business revenue composition includes 81.11% from self-developed products, 17.96% from agency products, and 0.93% from other supplementary sources [1] Financial Performance - As of June 30, 2023, Maike Bio reported a total of 35,000 shareholders, a decrease of 0.18% from the previous period. The average circulating shares per person increased by 0.25% to 14,031 shares [2] - For the first half of 2025, Maike Bio achieved an operating income of 1.075 billion yuan, a year-on-year decrease of 15.94%. The net profit attributable to the parent company was 34.04 million yuan, down 83.12% year-on-year [2] Dividend Distribution - Since its A-share listing, Maike Bio has distributed a total of 1.278 billion yuan in dividends, with 370 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2023, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder of Maike Bio, holding 5.1207 million shares, a decrease of 8.7749 million shares compared to the previous period [3]